Biomarkers Unbound — The Supreme Court’s Ruling on Diagnostic-Test Patents

Biomarkers Unbound — The Supreme Court’s Ruling on Diagnostic-Test Patents

Jason Karlawish argues for the advantages of public ownership and public-private partnerships for the development of biomarkers in his new NEJM piece “Biomarkers Unbound.” Penn faculty have been pioneers in the development of predictive biomarkers for Alzheimer’s Disease.

Categories: CNS News|